OphthalLogix Intelligence
Subscribe
Sign in
Home
Notes
Archive
About
China Rewrites Its Drug Pricing Rules for the First Time in Eleven Years
China's first national drug pricing framework since 2015 protects innovation from VBP, but device companies need a separate rule before anything…
Apr 24
•
OphthalLogix Intelligence
China’s Medical Device Listing Is No Longer a One-Time Filing
Zhejiang suspended 7 device products for code mismatch in April 2026. IOL listing is now an active compliance obligation, not one-time filing.
Apr 21
•
OphthalLogix Intelligence
When Guidance Becomes Mandate: What China’s New Cataract Surgery Standard Means for the IOL Market
The NHC’s 2026 operating regulation is not another expert consensus. For the first time, premium lens categories have a dedicated chapter in…
Apr 16
•
OphthalLogix Intelligence
China IOL Reimbursement Landscape — April 2026
A short reference PDF on current reimbursement regimes, VBP anchor prices, and policy developments through Q1 2026.
Apr 14
•
OphthalLogix Intelligence
The Three Reimbursement Regimes Hiding Inside China’s IOL Market
Why Beijing, Guangzhou and Shanghai now operate on three different payment logics, and what the 4th VBP round actually fixed in place.
Apr 14
•
OphthalLogix Intelligence
Decoding the "Hidden Ecosystem" of China’s Ophthalmic Procurement
Why official tenders are merely a "ticket to play." An exclusive memo for executives on mastering China’s clinical and administrative alignment.
Apr 6
•
OphthalLogix Intelligence
This site requires JavaScript to run correctly. Please
turn on JavaScript
or unblock scripts
